Product Data Sheet



Spautin-1

Cat. No.: HY-12990 CAS No.: 1262888-28-7 Molecular Formula: $C_{15}H_{11}F_2N_3$ Molecular Weight: 271.26

Target: Autophagy; Apoptosis; Deubiquitinase

Pathway: Autophagy; Apoptosis; Cell Cycle/DNA Damage

Powder -20°C Storage: 3 years

4°C 2 years

-80°C In solvent 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (184.32 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.6865 mL	18.4325 mL	36.8650 mL
	5 mM	0.7373 mL	3.6865 mL	7.3730 mL
	10 mM	0.3687 mL	1.8433 mL	3.6865 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 50% PEG300 >> 50% PBS Solubility: 10 mg/mL (36.86 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Spautin-1 is a specific and potent autophagy inhibitor which inhibits ubiquitin-specific peptidases, USP10 and USP13 with IC $_{50}$ s of 0.6-0.7 μ M.

In Vitro

Spautin-1 enhances imatinib mesylate (IM)-induced CmL cell apoptosis by reducing the expression of the anti-apoptotic proteins Mcl-1 and Bcl-2. The pro-apoptotic activity of spautin-1 is associated with activation of GSK3β, an important downstream effector of PI3K/AKT. Spautin-1 enhances IM-induced cytotoxicity in CmL cell line K562, decreasing the IC₅₀ from 1 to 0.5 μ M^[1]. The mechanism of spautin-1 acting on acute pancreatitis is associated with impaired autophagy

$inhibition \cite{[2]}.$

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Spautin-1 ameliorates the pathogenesis of acute pancreatitis induced by cerulein or L-arginine. Spautin-1 pretreatment significantly diminishes the elevation of serum amylase and lipase levels, which are indicative of trypsin activity. Increasing levels of serum TNF α caused by cerulein are inhibited in the presence of spautin-1. Spautin-1 treatment can ameliorate the inflammation damage induced by cerulein, such as edema, degeneration, coagulative necrosis and infiltration of inflammatory cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay [1]

Spautin-1 is dissolved in DMSO. Cell proliferation is evaluated using CCK-8 kit. K562 cells (1×10^5 /mL) are seeded into 96-well plates in triplicate and then treated with 125 to 4,000 nM IM alone or in combi¬nation with spautin-1 ($10 \mu M$). After 48 h of incubation, $10 \mu L$ of CCK-8 reagent is added to each well. Four hours later, the absorbance is read at 450 nm using a microplate reader^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration [2]

Mice: In this study, mice models with acute pancreatitis, including cerulein- and L-arginine-induced models, are constructed. For the cerulein-induced model, four intraperitoneal injections of cerulein (50 μg/kg body weight) are given consecutively at hourly intervals; The L-arginine-induced model received hourly intraperitoneal injections of 1.4 g/kg (optimal dosage for this study) L-arginine three times^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2022 Mar 31;13(1):1700.
- Cell Death Differ. 2022 Dec 16.
- J Cell Mol Med. 2021 May 2.
- Microbiol Spectr. 2023 Jun 6;e0474522.
- · Cancer Res Commun. 2024 Mar 11.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Shao S, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol. 2014 May;44(5):1661-1668.

[2]. Xiao J, et al. Spautin-1 Ameliorates Acute Pancreatitis via Inhibiting Impaired Autophagy and Alleviating Calcium Overload. Mol Med. 2016 Aug 18;22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA